Anxiety.
Conditions
Interventions
Sponsors
Universidade do Sul de Santa Catarina
Universidade do Sul de Santa Catarina
Eligibility
Inclusion criteria
Inclusion criteria: Present a medical diagnosis of depression; being in pharmacological treatment; age group between 18 and 60 years; female and male
Exclusion criteria
Exclusion criteria: Individuals who are under nutritional monitoring with a nutritionist; following a specific eating plan; individuals with diabetes mellitus (type I or II); epilepsy, people with hypersensitivity to light; immunosuppressive, oncological and infectious diseases; pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in the level of depression, assessed using the Hamilton Depression Scale with a 20% reduction in scale score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in quality of life, assessed by applying the SF-36 Questionnaire, from the English Medical Outcomes study 36-item Short-Form Health Survey, in the translated and validated version for Portuguese, with a 20% increase in the score.;Improvement in the level of anxiety, to assess the level of anxiety, the Hamilton Anxiety Scale will be used, with a 20% reduction in the scale's score.;Improvement in sleep quality, for sleep quality assessment, the Pittsburgh Sleep Quality Index will be used, in the translated and validated version for Portuguese, with a 20% reduction in the questionnaire score.;Improvement in the level of stress and resilience, to measure the level of stress, the Perceived Stress Scale will be used, with a 20% reduction in the questionnaire score.;Improvement in the usual diet, the 24-hour recall will be used to assess the eating pattern of the participants. This is a self-applicable tool, which will contain information regarding the participant's 24 hours of food, with details on meals taken and times, food consumed and their respective quantities. A 20% improvement in food is expected.;Improvement in brain wave activity, brain activity will be measured by electroencephalogram, a 20% increase in alpha waves is expected. ;Improvement in heart rate variability will be assessed through heart rate variability with Nerve-Express software. A 20% increase in heart rate variability is expected.;Serum dosages of tumor necrosis factor (TNF), interleukin-1ß (IL-1ß), interleukin-6 (IL-6), interleukin-10 (IL-10), as well as leptin, melatonin, brain-derived neurotrophic factor (BDNF) and ß-enolase will be performed by the ELISA method (Enzyme-Linked Immunosorbent Assay), through the DuoSet ELISA kit for humans, according to the instructions of the kit manufacturer. 20% reductions are expected for tumor necrosis factor (TNF), interleukin-1 (IL-1ß) and interleukin-6 (IL-6), as well as a 20% increase for ß-enolase, interleukin-10 (IL-10), leptin, melatonin | — |
Countries
Brazil
Contacts
Public ContactDaniel Martins
Outcome results
None listed